Today, Fool.com analysts David Williamson and Max Macaluso look at the three big events driving Abbott Labs today. Topping the list is the impressive results for its hepatitis C drug, which appears significantly more successful than Gilead's comparable drug and bodes well for the planned AbbVie spinoff. On the other hand, the company has had to discontinue phase 3 trials for its potential kidney disease and diabetes drug, and investors should keep an eye on the looming patent cliff.
The biotech space is full of ebbs and flows in company fortunes, and if you don't know how to play the sector, you can get burned. See more in the following video.
